BioCardia Reports Decreased Net Loss and Increased Assets in Q2 2026

BioCardia, Inc. reported its financial results for the second quarter of 2026, revealing a net loss of $1.6 million, a decrease from a net loss of $2.0 million in the same period last year. For the six months ending June 30, 2026, the company recorded a net loss of $3.9 million, down from $4.8 million in the prior year. The reduction in losses is attributed to a decrease in research and development expenses, which fell to $893,000 in the second quarter from $1.4 million in the same quarter of 2025, primarily due to the closeout of the CardiAMP Heart Failure Trial. Total costs and expenses for the second quarter were $1.6 million, compared to $2.1 million in the previous year.

In terms of financial position, BioCardia's total assets increased to $4.8 million as of June 30, 2026, up from $3.4 million at the end of 2025. The company reported cash and cash equivalents of approximately $4.1 million, a significant increase from $2.5 million at the end of the previous fiscal year. This increase was bolstered by the sale of 4 million shares of common stock, generating gross proceeds of about $5.1 million during the second quarter. However, the company continues to face challenges, with an accumulated deficit of approximately $172.2 million as of June 30, 2026.

Operationally, BioCardia is advancing its clinical programs, particularly the CardiAMP autologous cell therapy for ischemic heart failure and chronic myocardial ischemia. The company has received regulatory support from the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) for its CardiAMP therapy, which is expected to target approximately 20,000 patients in Japan. Additionally, the U.S. Food and Drug Administration (FDA) has indicated that ongoing trials may support the premarket approval of the CardiAMP Cell Therapy System.

Looking ahead, BioCardia anticipates continued operating losses and negative cash flows, projecting that its current cash reserves will not be sufficient to fund operations beyond January 2027. The company plans to seek additional capital through various means, including potential licensing arrangements and equity financing. Management has expressed confidence in its ability to raise the necessary funds, although it acknowledges the inherent risks and uncertainties associated with its development programs and market conditions.